Press release
ER+/ HER2 -ve Breast Cancer Pipeline Assessment (2023) Covering Clinical Trials, Emerging Therapies, FDA, EMA, and PMDA Approvals | Astrazeneca, BeiGene, Pfizer, Novartis, Roche, Eli Lilly, EQRx, Radius Pharma
"ER+/ HER2 -ve Breast Cancer Pipeline Insight, 2023" report by DelveInsight provides a comprehensive analysis of the ongoing clinical development activities and growth prospects across the ER+/ HER2 -ve Breast Cancer Therapeutics Market.
The report provides a detailed description of the ER+/ HER2 -ve Breast Cancer drugs, including the mechanism of action, type, stage, route of administration, molecule type, clinical studies, inactive pipeline products, and NDA approvals (if any). The report also covers commercial and clinical activities of the pipeline products from the pre-clinical developmental phase to the marketed stage. Additionally, it presents the ongoing developments in the therapeutics segment, including collaborations, licensing, mergers & acquisitions (M&A), funding, designations, and other product-related details.
Get a Detailed Overview of the ER+/ HER2 -ve Breast Cancer Clinical Trial Activities and Regulatory Developments in the domain:
https://www.delveinsight.com/report-store/er-her2-ve-breast-cancer-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr
ER+/ HER2 -ve Breast Cancer Pipeline Analysis
The report provides insights into:
• The report provides detailed insights into the key companies that are developing ER+/ HER2 -ve Breast Cancer therapies.
• The report also evaluates different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for ER+/ HER2 -ve Breast Cancer treatment.
• It analyzes the key companies involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• It navigates the emerging ER+/ HER2 -ve Breast Cancer drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement, and financing details for future advancement in the ER+/ HER2 -ve Breast Cancer treatment market.
Learn More about the Clinical and Commercial Development Activities in the ER+/ HER2 -ve Breast Cancer Therapeutics Domain:
https://www.delveinsight.com/report-store/er-her2-ve-breast-cancer-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr
The Report Covers the Emerging ER+/ HER2 -ve Breast Cancer Therapies Under Different Phases of Clinical Development Like -
• Late-stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I)
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
Route of Administration
ER+/ HER2-VE Breast Cancer pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
• Infusion
• Intradermal
• Intramuscular
• Intranasal
• Intravaginal
• Oral
• Parenteral
• Subcutaneous
• Topical
Molecule Type
Products have been categorized under various Molecule types such as
• Vaccines
• Monoclonal Antibody
• Peptides
• Polymer
• Small molecule
Request for Sample PDF to Understand More About the ER+/ HER2 -ve Breast Cancer Treatment Outlook and Future Perspectives:
https://www.delveinsight.com/sample-request/er-her2-ve-breast-cancer-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr
ER+/ HER2 -ve Breast Cancer Therapeutics Analysis
Several major pharma and biotech companies are developing therapies for ER+/ HER2-VE Breast Cancer. Currently, Astrazeneca is leading the therapeutics market with its ER+/ HER2-VE Breast Cancer drug candidates in the most advanced stage of clinical development.
ER+/ HER2 -ve Breast Cancer Companies in the Therapeutics Market Include:
BeiGene, H3 Biomedicine, AstraZeneca, Olema Pharmaceuticals, CytomX Therapeutics, G1 Therapeutics, Sanofi, Jiangsu HengRui Medicine, Radius Pharmaceuticals, Sanofi, AstraZeneca, Eli Lilly, EQRx, Gilead, Sermonix Pharmaceuticals, Evgen Pharma, Tyme, Roche, Genentech, Daiichi Sankyo, Veru, and many others.
Emerging and Marketed ER+/ HER2 -ve Breast Cancer Therapies Covered in the Report Include:
• AZD9833: Astrazeneca
• BGB-290: BeiGene
• IBRANCE (palbociclib): Pfizer
• AFINITOR (everolimus): Novartis
• Elacestrant: Radius Pharmaceuticals
• Giredestrant (RG6171, GDC-9545): Roche
• Camizestrant (AZD9833): AstraZeneca
• LY3484356 (imlunestrant): Eli Lilly
• Lerociclib (EQ132): EQRx
And Many Others
Get an in-depth Assessment of the Emerging Therapies and ER+/ HER2 -ve Breast Cancer Companies Actively Working in the Market:
https://www.delveinsight.com/sample-request/er-her2-ve-breast-cancer-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr
Table of Content
1. Report Introduction
2. Executive Summary
3. ER+/ HER2 -ve Breast Cancer Current Treatment Patterns
4. ER+/ HER2 -ve Breast Cancer - DelveInsight's Analytical Perspective
5. Therapeutic Assessment
6. ER+/ HER2 -ve Breast Cancer Late-Stage Products (Phase-III)
7. ER+/ HER2 -ve Breast Cancer Mid-Stage Products (Phase-II)
8. Early Stage Products (Phase-I)
9. Pre-clinical Products and Discovery Stage Products
10. Inactive Products
11. Dormant Products
12. ER+/ HER2 -ve Breast Cancer Discontinued Products
13. ER+/ HER2 -ve Breast Cancer Product Profiles
14. ER+/ HER2 -ve Breast Cancer Companies
15. ER+/ HER2 -ve Breast Cancer Drugs
16. Dormant and Discontinued Products
17. ER+/ HER2 -ve Breast Cancer Unmet Needs
18. ER+/ HER2 -ve Breast Cancer Future Perspectives
19. ER+/ HER2 -ve Breast Cancer Analyst Review
20. Appendix
21. Report Methodology
Get Detailed Insights About the Reports Offerings:
https://www.delveinsight.com/sample-request/er-her2-ve-breast-cancer-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr
-------------------------------------------- xx --------------------------------------------
Other Trending Healthcare Reports by DelveInsight
Erectile Dysfunction Market
https://www.delveinsight.com/report-store/erectile-dysfunction-market
Varicose Ulcer Market
https://www.delveinsight.com/report-store/varicose-ulcer-market
Trastuzumab Biosimilars
https://www.delveinsight.com/report-store/trastuzumab-biosimilars-insight
Poly (ADP-Ribose) Polymerase 1 (PARP) Inhibitor Pipeline Insight
https://www.delveinsight.com/report-store/poly-adp-ribose-polymerase-1-parp-inhibitor-pipeline-insight
Stereotactic Surgery Devices Market
https://www.delveinsight.com/report-store/stereotactic-surgery-devices-market
Acute lymphocytic leukemia (ALL) Market
https://www.delveinsight.com/report-store/acute-lymphocytic-leukemia-all-market
Eczema Market
https://www.delveinsight.com/report-store/eczema-market
Traumatic Brain Injury Market
https://www.delveinsight.com/report-store/traumatic-brain-injury-market
Hemostats Market
https://www.delveinsight.com/report-store/hemostats-market
Gastroesophageal Reflux Disease (GERD) Market
https://www.delveinsight.com/report-store/gastroesophageal-reflux-disease-gerd-market
Peripheral Vascular Devices Market
https://www.delveinsight.com/report-store/peripheral-vascular-devices-market
Obesity Market
https://www.delveinsight.com/report-store/weight-loss-weight-management-obesity-market
Urinary Incontinence Market
https://www.delveinsight.com/report-store/urinary-incontinence-market
Hemostasis Market
https://www.delveinsight.com/report-store/hemostasis-market
Intracardiac Echocardiography Devices Market
https://www.delveinsight.com/report-store/intracardiac-echocardiography-devices-market
Emphysema Market
https://www.delveinsight.com/report-store/emphysema-market
Factor Xa Inhibitor Market
https://www.delveinsight.com/report-store/factor-xa-inhibitor-market
Undifferentiated Pleomorphic Sarcoma Market
https://www.delveinsight.com/report-store/undifferentiated-pleomorphic-sarcoma-market
Carcinoid Tumor Syndrome Market
https://www.delveinsight.com/report-store/carcinoid-tumor-syndrome-market
Primary Progressive Multiple Sclerosis (PPMS) Market
https://www.delveinsight.com/report-store/primary-progressive-multiple-sclerosis-ppms-market
Thalassemia Market
https://www.delveinsight.com/report-store/thalassemia-market
Preeclampsia Market
https://www.delveinsight.com/report-store/preeclampsia-market
Chronic Periodontitis Market
https://www.delveinsight.com/report-store/chronic-periodontitis-market
Cryptococcosis Market
https://www.delveinsight.com/report-store/cryptococcosis-market
Exocrine Pancreatic Insufficiency Market
https://www.delveinsight.com/report-store/exocrine-pancreatic-insufficiency-market
Papilloma MarketRespiratory Distress Syndrome Market
https://www.delveinsight.com/report-store/respiratory-distress-syndrome-market
Sinusitis Market
https://www.delveinsight.com/report-store/sinusitis-market
Childhood Atropine For Myopia Progression Market
https://www.delveinsight.com/report-store/childhood-atropine-for-myopia-progression-market
Cushing's Syndrome Market
https://www.delveinsight.com/report-store/cushings-syndrome-market
Skin Burns Market
https://www.delveinsight.com/report-store/skin-burns-market
Adeno-Associated Virus Vectors in Gene Therapy Market
https://www.delveinsight.com/report-store/adeno-associated-virus-vectors-in-gene-therapy-market
Autism Spectrum Disorder Market
https://www.delveinsight.com/report-store/autism-spectrum-disorder-asd-market
Contact Info:
Shruti Thakur
Manager - Marketing & International Branding
Email: info@delveinsight.com
428, D21 Corporate Park, Sector-21, Dwarka, New Delhi-110077, India
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release ER+/ HER2 -ve Breast Cancer Pipeline Assessment (2023) Covering Clinical Trials, Emerging Therapies, FDA, EMA, and PMDA Approvals | Astrazeneca, BeiGene, Pfizer, Novartis, Roche, Eli Lilly, EQRx, Radius Pharma here
News-ID: 3150749 • Views: …
More Releases from DelveInsight Business Research LLP
Genital Warts Pipeline Insights Report 2025 | DelveInsight
DelveInsight's, "Genital Warts Pipeline Insight 2025" report provides comprehensive insights about 30+ companies and 30+ pipeline drugs in Genital Warts pipeline landscape. It covers the Genital Warts pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Explore the comprehensive insights by DelveInsight and stay ahead…
Traumatic Brain Injury Pipeline Drugs Report 2025 | DelveInsight
DelveInsight's "Traumatic Brain Injury Pipeline Insight 2025" report provides comprehensive insights about 20+ companies and 22+ pipeline drugs in Tthe raumatic Brain Injury pipeline landscape. It covers the Traumatic Brain Injury pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Traumatic Brain Injury pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Explore…
Bone Metastasis Pipeline Assessment Report 2025 | DelveInsight
DelveInsight's, "Bone Metastases Pipeline Insight, 2025," report provides comprehensive insights about 10+ companies and 10+ pipeline drugs in Bone Metastases pipeline landscape. It covers the Bone Metastasis pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Bone Metastasis pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Explore the comprehensive insights by DelveInsight…
Acquired Immunodeficiency Syndrome Treatment Market Size Report 2032 | DelveInsi …
DelveInsight's "Acquired Immunodeficiency Syndrome Market Insights, Epidemiology, and Market Forecast-2032′′ report offers an in-depth understanding of the Acquired Immunodeficiency Syndrome, historical and forecasted epidemiology as well as the Acquired Immunodeficiency Syndrome market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.
To Know in detail about the Acquired Immunodeficiency Syndrome market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Acquired Immunodeficiency Syndrome Market…
More Releases for ER+/
ER+/HER2- Breast Cancer Market Insights and Future Outlook
Introduction
Estrogen receptor-positive, HER2-negative (ER+/HER2-) breast cancer is the most common molecular subtype of breast cancer, accounting for nearly 70% of all breast cancer diagnoses worldwide. This classification is defined by tumors that express estrogen receptors (ER) but lack human epidermal growth factor receptor 2 (HER2) amplification. The subtype's dominance in global oncology has positioned it as the central focus for therapeutic innovation, guidelines development, and precision medicine strategies.
Historically managed with…
Er YAG Laser Market Outlook and Future Projections for 2030
An Er:YAG laser (erbium-doped yttrium aluminum garnet) is a type of solid-state laser commonly used in medical and cosmetic procedures. It emits light at a wavelength of 2940 nm, which is highly absorbed by water, making it effective for precise tissue ablation and resurfacing. This laser is popular in dermatology and dentistry for its ability to gently remove layers of skin or tissue with minimal thermal damage and quick healing.
The…
Optical Brightener ER-I and ER-II Market Size Unveiled: Trends and Projections
The global Optical Brightener ER-I and ER-II market is carefully researched in the report while largely concentrating on top players and their business tactics, geographical expansion, market segments, competitive landscape, manufacturing, and pricing and cost structures. Each section of the research study is specially prepared to explore key aspects of the global Optical Brightener ER-I and ER-II market. For instance, the market dynamics section digs deep into the drivers, restraints,…
Optical Brightener ER-I and ER-II Market by Key Players,Competitive landscape an …
LOS ANGELES, United States: The global Optical Brightener ER-I and ER-II market is analyzed in quite some detail in the report with a strong focus on the competitive landscape, segmentation, market dynamics, and regional market expansion. The report includes a thorough assessment of the business of key players operating in the global Optical Brightener ER-I and ER-II market. With deeper qualitative and quantitative analysis of the global Optical Brightener ER-I and…
Optical Brightener ER-I and ER-II Market Trends, Regional Overview, Leading Comp …
LOS ANGELES, United States: The global Optical Brightener ER-I and ER-II market is carefully researched in the report while largely concentrating on top players and their business tactics, geographical expansion, market segments, competitive landscape, manufacturing, and pricing and cost structures. Each section of the research study is specially prepared to explore key aspects of the global Optical Brightener ER-I and ER-II market. For instance, the market dynamics section digs deep…
ER Wagner adding 600-ton Servo Punch Press
Milwaukee-based ER Wagner announced it will have a new 600-ton Servo Punch Press available for production in late 2017, greatly increasing ER Wagner’s metal stamping capabilities.
The Nidec Minster Corporation machine, which will be a part of ER Wagner’s new 157,000-square-foot corporate headquarters and state of the art manufacturing facility currently under construction in the Village of Menomonee Falls, Wis., is latest technology in metal stamping, giving the company the ability…
